• 280+
    Pharmaceutical Partners
  • 150+
    Biomarker Assays
  • 300+
    Method Validations
  • 40+

Clinical Testing

Patient Testing for Precision Medicine

  • Pan solid tumor
    Meet the diverse demands from clinicians and patients, MEDx Translational Medicine (MEDx) has developed a series of solid tumor tests, including pan-cancer gene panel tests, single cancer gene panel assays, and immunohistochemistry (IHC).
  • Hematologic Malignancy
    Most recently, molecular diagnostic products using PCR and next-generation sequencing (NGS) have significantly improved the understanding of molecular mechanism of hematological malignancies, leading to the right choice of molecular targeting drugs for precision therapy for the individual patients in clinic.
  • Infectious Disease
    Infectious Disease

About MEDx

Translational Medicine

MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.

Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient  stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.

view more >>


MEDx and illumina jointly promote gene sequencing technology to help global new drug research

In the development process of innovative drugs, the accompanying diagnosis is like a indicating lamp

MEDx's Debut at 2023 Medlab Asia & Asia Health a Complete Success

From August 16 to 18, MEDx participated in the 2023 MedLab Asia held at the IMPACT Exhibition Centre

MEDx Partners with Junshi Biosciences in the Innovative Co-Development of Companion Diagnostics

On May 22, 2023, Shanghai Junshi Biosciences Co., Ltd. (hereinafter referred to as "Junshi Bios

HRD Panel of MEDx

Homologous Recombination Repair (HRR) and Poly ADP-ribose Polymerase (PARP) Repair are two important

MEDx Obtained the Global Authorization of Abcam

MEDx announced the expansion of global cooperation with its strategic partner Abcam (AIM:ABC; NASDAQ

Meet MEDx at Medlab Middle East | Dubai 2023

The leading healthcare event –Medlab Middle East is coming. Spread over 45,000 sqm of space, this c

What is minimal residual disease (MRD)?

Minimal Residual Disease (MRD) was initially proposed in blood disorders, which refers to the presen

A Potential CDx Biomarker For Targeted Therapy In Non-Small Cell lung Cancer——MET

The morbidity and mortality of lung cancer rank first among malignant tumors, and the disease burden

MEDx NGS Panel Solutions in Solid Tumors

Next-generation sequencing (NGS) can simultaneously sequence millions or even billions of DNA molecu

MEDx NGS Panel Solutions in Solid Tumors

Next-generation sequencing (NGS) can simultaneously sequence millions or even billions of DNA molecu

Companion Diagnostics- an Effective Tool for Medication Guidance

A companion diagnostic (CDx) is a medical device, often an in vitro device, which provides informati